North America Molecular Diagnostics Market Forecast to 2030 - Regional Analysis - by Disease Area, Technology, Product and Services, and End User

List of Tables

The North America molecular diagnostics market is expected to grow from US$ 8,056.48 million in 2022 to US$ 20,740.38 million by 2030. It is estimated to grow at a CAGR of 12.5% from 2022 to 2030.

Development of New Products and Increase in Demand for Point-of-Care Testing Fuels North America Molecular Diagnostics Market

Point-of-care testing is a branch of medicine with a rapidly evolving analytical scope and clinical application. Point-of-care testing solution providers offer products for various evaluations, ranging from blood glucose measurement to viscoelastic coagulation assays. Eliminating the time of transportation and preparation of clinical samples, these tests enable professionals to make clinical decisions about additional testing or therapy in less time. This emerging healthcare solution is being aggressively adopted by patients and healthcare service providers. Point-of-care assays are extensively used in therapeutics, diagnostics, and patient monitoring applications, among others. Moreover, point-of-care products and services help healthcare providers in meeting patients' demand for at-home medical care. These products and services proved specifically helpful during the COVID-19 pandemic by allowing patients to take tests from their homes instead of traveling to diagnostic or treatment facilities, thereby lowering the risk of infection. Thus, the rising demand for point-of-care testing benefits the molecular diagnostics market.

North America Molecular Diagnostics Market Overview

The North America molecular diagnostics market has been segmented into the US, Canada, and Mexico. The increasing adoption of technologically advanced products, rise in research & development activities, presence of large healthcare businesses, and growing use of molecular diagnostics are among the key factors propelling the growth of the molecular diagnostics market in this region. The US held the largest share of the North America molecular diagnostics market in 2022.

North America Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Million)

North America Molecular Diagnostics Market Segmentation

The North America molecular diagnostics market is segmented into disease area, technology, product and services, end user, and country.

Based on disease area, the North America molecular diagnostics market is segmented into infectious disease, oncology, genetic testing, cardiac diseases, immune system disorders, and others. The infectious disease segment registered the largest North America molecular diagnostics market share in 2022.

Based on technology, the North America molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarrays, and others. The polymerase chain reaction (PCR) segment registered the largest North America molecular diagnostics market share in 2022. The polymerase chain reaction (PCR) is further subsegmented into RT-PCR, qPCR, multiplex PCR, and others.

Based on product and services, the North America molecular diagnostics market is segmented into assays and kits, instruments, and services and software. The assays and kits segment registered the largest North America molecular diagnostics market share in 2022.

Based on end users, the North America molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics, research and academic institutes, and others. The diagnostic laboratories segment held the largest North America molecular diagnostics market share in 2022.

Based on country, the North America molecular diagnostics market has been categorized into the US, Canada, and Mexico. The US dominated the North America molecular diagnostics market in 2022.

Abbott Laboratories, Agilent Technologies Inc, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Qiagen NV, bioMerieux SA, Illumina Inc, Danaher, Siemens Healthineers AG, Novartis AG, and TBG Diagnostics Limited are some of the leading companies operating in the North America molecular diagnostics market.

Product Code: TIPRE00026717

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Molecular Diagnostics Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis

5. North America Molecular Diagnostics Market - Key Industry Dynamics

5.1 Key Market Drivers:
- 5.1.1 Development of New Products and Increase in Demand for Point-of-Care Testing
- 5.1.2 Surging Prevalence of Associated Diseases
5.2 Market Restraints
- 5.2.1 Limitations Associated with Molecular Testing
5.3 Market Opportunities
- 5.3.1 Advancements in Molecular Diagnostics Technologies
5.4 Future Trends
- 5.4.1 Molecular Diagnostics in Personalized Medicine
5.5 Impact Analysis:

6. Molecular Diagnostics Market - North America Market Analysis

6.1 North America Molecular Diagnostics Market Revenue (US$ Mn), 2022 - 2030

7. North America Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Disease Area

7.1 Overview
7.2 North America Molecular Diagnostics Market Revenue Share, by Disease Area 2022 & 2030 (%)
7.3 Oncology
- 7.3.1 Overview
- 7.3.2 Oncology: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Infectious Disease
- 7.4.1 Overview
- 7.4.2 Infectious Disease: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Genetic Testing
- 7.5.1 Overview
- 7.5.2 Genetic Testing: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Cardiac Diseases
- 7.6.1 Overview
- 7.6.2 Cardiac Diseases: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Immune System Disorders
- 7.7.1 Overview
- 7.7.2 Immune System Disorders: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
7.8 Others
- 7.8.1 Overview
- 7.8.2 Others: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Technology

8.1 Overview
8.2 North America Molecular Diagnostics Market Revenue Share, by Technology 2022 & 2030 (%)
8.3 Polymerase Chain Reaction
- 8.3.1 Overview
- 8.3.2 PCR: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 RT-PCR
    - 8.3.2.1.1 Overview
- 8.3.3 RT-PCR: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.3.1 qPCR
    - 8.3.3.1.1 Overview
- 8.3.4 PCR: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.4.1 Multiplex PCR
    - 8.3.4.1.1 Overview
- 8.3.5 Multiplex PCR: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.5.1 Others
    - 8.3.5.1.1 Overview
- 8.3.6 Others: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 8.4.1 Overview
- 8.4.2 Isothermal Nucleic Acid Amplification Technology (INAAT): North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 DNA Sequencing and Next-Generation Sequencing (NGS)
- 8.5.1 Overview
- 8.5.2 DNA Sequencing and Next-Generation Sequencing (NGS): North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
8.6 DNA Microarrays
- 8.6.1 Overview
- 8.6.2 DNA Microarrays: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
8.7 In-Situ Hybridization (ISH)
- 8.7.1 Overview
- 8.7.2 In-Situ Hybridization (ISH): North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Product and Services

9.1 Overview
9.2 North America Molecular Diagnostics Market Revenue Share, by Product and Services 2022 & 2030 (%)
9.3 Assays and Kits
- 9.3.1 Overview
- 9.3.2 Assays and Kits: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Instruments
- 9.4.1 Overview
- 9.4.2 Instruments: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Services and Software
- 9.5.1 Overview
- 9.5.2 Services and Software: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Molecular Diagnostics Market - Revenue and Forecast to 2030 - by End User

10.1 Overview
10.2 North America Molecular Diagnostics Market Revenue Share, by End User 2022 & 2030 (%)
10.3 Hospitals and Clinics
- 10.3.1 Overview
- 10.3.2 Hospitals and Clinics: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
10.4 Diagnostics Laboratories
- 10.4.1 Overview
- 10.4.2 Diagnostics Laboratories: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
10.5 Research and Academic Institutes
- 10.5.1 Overview
- 10.5.2 Research and Academic Institutes: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)
10.6 Others
- 10.6.1 Overview
- 10.6.2 Others: North America Molecular Diagnostics Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Molecular Diagnostics Market - Country Analysis

11.1 North America Molecular Diagnostics Market, Revenue and Forecast To 2030
- 11.1.1 Overview
  - 11.1.1.1 North America Molecular Diagnostics Market, by Country
- 11.1.2 US
  - 11.1.2.1 Overview
- 11.1.3 US Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.4 US Molecular Diagnostics Market, by Disease Area
- 11.1.5 US Molecular Diagnostics Market, by Technology
  - 11.1.5.1 US Molecular Diagnostics Market, by Polymerase Chain Reaction (PCR)
- 11.1.6 US Molecular Diagnostics Market, by Product and Services
- 11.1.7 US Molecular Diagnostics Market, by End User
- 11.1.8 Canada
  - 11.1.8.1 Overview
- 11.1.9 Canada Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.10 Canada Molecular Diagnostics Market, by Disease Area
- 11.1.11 Canada Molecular Diagnostics Market, by Technology
  - 11.1.11.1 Canada Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
- 11.1.12 Canada Molecular Diagnostics Market, by Product and Services
- 11.1.13 Canada Molecular Diagnostics Market, by End User
- 11.1.14 Mexico
  - 11.1.14.1 Overview
- 11.1.15 Mexico Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.16 Mexico Molecular Diagnostics Market, by Disease Area
- 11.1.17 Mexico Molecular Diagnostics Market, by Technology
  - 11.1.17.1 Mexico Molecular Diagnostics Market, Polymerase Chain Reaction (PCR)
- 11.1.18 Mexico Molecular Diagnostics Market, by Product and Services
- 11.1.19 Mexico Molecular Diagnostics Market, by End User

12. North America Molecular Diagnostics Market Industry Landscape

12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market (%)
12.3 Organic Developments
- 12.3.1 Overview
12.4 Inorganic Developments
- 12.4.1 Overview

13. North America Molecular Diagnostics Market, Key Company Profiles

13.1 Abbott Laboratories
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Agilent Technologies Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 F. Hoffmann-La Roche Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Qiagen NV
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 bioMerieux SA
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Illumina Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Danaher
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Siemens Healthineers AG
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Novartis AG
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 TBG Diagnostics Limited
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments

14. Appendix

14.1 About Us
14.2 Glossary of Terms